Last updated on October 2018

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia


Brief description of study

To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).

Clinical Study Identifier: NCT02871778

Contact Investigators or Research Sites near you

Start Over

Nina Church

Birmingham, AL United States

Nina Church

Palo Alto, CA United States

Nina Church

Aurora, CO United States

Nina Church

Miami, FL United States

Nina Church

Tampa, FL United States

Nina Church

Chicago, IL United States

Nina Church

Indianapolis, IN United States

Nina Church

Iowa City, IA United States

Nina Church

Kansas City, KS United States

Nina Church

Boston, MA United States

Nina Church

Ann Arbor, MI United States

Nina Church

Minneapolis, MN United States

Nina Church

Saint Louis, MO United States

Nina Church

New York, NY United States

Nina Church

Chapel Hill, NC United States

Nina Church

Cleveland, OH United States

Nina Church

Philadelphia, PA United States

Nina Church

Columbia, SC United States

Nina Church

Seattle, WA United States

Nina Church

Toronto, ON Canada

Nina Church

Montreal, QC Canada

Nina Church

Copenhagen, Denmark

Nina Church

Munster, Germany

Nina Church

Hannover, Germany

Nina Church

Heidelberg, Germany

Nina Church

Pisa, Italy

Nina Church

Rotterdam, Netherlands

Nina Church

Rabka-Zdroj, Poland

Nina Church

Cambridge, United Kingdom

Nina Church

London, United Kingdom

Nina Church

Southampton, United Kingdom

Nina Church

Washington, WA United States

Nina Church

Amsterdam, Netherlands